Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.
Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the United States, following receipt of FDA approval for its home pregnancy ultrasound product.
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia.
SurGenTec®, a medical device innovation company focused on advancing treatment options for orthopedic and spine surgery, announced FDA clearance of its ION-C™ Facet Fixation System.
PICO IV, a leading innovator in sterile cannabidiol (CBD) solutions, announced a closely coordinated clinical collaboration with BrainThrive, PC, a neurology and diagnostic testing center in Westlake Village, California.
AptarGroup, Inc. a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being utilized in CastleVax’s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate.
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning.
Dechra, a global leader in veterinary specialty care, today shares the FDA approval of Emeprev™ (maropitant citrate) Injectable Solution, the first FDA-approved bioequivalent injectable solution to the most widely used antiemetic for dogs and cats.
BD a leading global medical technology company, announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.
Citius Oncology, Inc. the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.